Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib

Australas J Dermatol. 2019 Aug;60(3):e242-e243. doi: 10.1111/ajd.13001. Epub 2019 Feb 6.

Authors

Federica Scarfì¹, Barbara Melotti², Giulia Veronesi¹, Giulia Maria Ravaioli¹, Carlotta Baraldi^{1

3}, Martina Lambertini¹, Annalisa Patrizi¹, Emi Dika¹

Affiliations

¹ Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
² Oncology Unit, Department of Diagnostic Medicine and Prevention, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy.
³ Laboratory of Dermatopathology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

PMID: 30724336
DOI: 10.1111/ajd.13001

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Female
Humans
Imidazoles / therapeutic use*
Melanoma / drug therapy
Melanoma / secondary*
Middle Aged
Oximes / therapeutic use*
Pyridones / therapeutic use*
Pyrimidinones / therapeutic use*
Skin Neoplasms / drug therapy
Skin Neoplasms / pathology*
Sweet Syndrome / etiology*
Sweet Syndrome / pathology

Substances

Antineoplastic Agents
Imidazoles
Oximes
Pyridones
Pyrimidinones
trametinib
dabrafenib